Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation

Pharmacogenomics

Volumn 14, Issue 1, 2013, Pages 75-87

  Hassan, Moustapha ^a,b   Andersson, Borje S ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

aldehyde dehydrogenase; busulfan; cyclophosphamide; CYP450; GSH; GST; pharmacogenetic; pharmacokinetics; polymorphism; stem cell transplantation

Indexed keywords

ACETYLCYSTEINE; ALDEHYDE DEHYDROGENASE; AMIODARONE; BUSULFAN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; ERYTHROMYCIN; FLUCONAZOLE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE A1; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; MELPHALAN; METRONIDAZOLE; MIDAZOLAM; PHOSPHORAMIDE MUSTARD; POSACONAZOLE; PROTEIN TYROSINE KINASE INHIBITOR; QUINIDINE; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY; UNINDEXED DRUG;

ALOPECIA; AREA UNDER THE CURVE; CARCINOGENICITY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISPOSITION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSPORT; GENETIC ANALYSIS; GONAD DYSFUNCTION; GRAFT VERSUS HOST REACTION; HEART DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGIC CYSTITIS; HEPATORENAL SYNDROME; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INDIVIDUALIZATION; INTERSTITIAL PNEUMONIA; LIVER DYSFUNCTION; LIVER VENOOCCLUSIVE DISEASE; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; PATIENT CARE; PERSONALIZED MEDICINE; PHARMACOGENETICS; REVIEW; TERATOGENICITY; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ANIMALS; BUSULFAN; CYCLOPHOSPHAMIDE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PHARMACOGENETICS; TRANSPLANTATION CONDITIONING;

EID: 84871431325     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.185     Document Type: Review

References (112)

1. Ciurea SO, Andersson BS. Busulfan in hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 15(5), 523-536 (2009).
2. Likhacheva AS, Nikolin VP, Popova NA et al. Integration of human DNA fragments into the cell genomes of certain tissues from adult mice treated with cytostatic cyclophosphamide in combination with human DNA. Gene Ther. Mol. Biol. 11, 185-201 (2007).
3. Friedman HS, Johnson SP, Dong Q et al. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res. 57(14), 2933-2936 (1997). (Pubitemid 27315042)
4. Sladek NE, Dockham PA, Lee MO. Human and mouse hepatic aldehyde dehydrogenases important in the biotransformation of cyclophosphamide and the retinoids. Adv. Exp. Med. Biol. 284, 97-104 (1991).
5. Xie HJ, Griskevicius L, Stahle L et al. Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. Eur. J. Pharm. Sci. 27(1), 54-61 (2006). (Pubitemid 41728255)
6. Xie HJ, Lundgren S, Broberg U, Finnstrom N, Rane A, Hassan M. Effect of cyclophosphamide on gene expression of cytochromes P450 and b-actin in the HL-60 cell line. Eur. J. Pharmacol. 449(3), 197-205 (2002).
7. Hassan M, Ehrsson H. Urinary metabolites of busulfan in the rat. Drug Metab. Dispos. 15(3), 399-402 (1987). (Pubitemid 17096524)
8. Hassan M, Ehrsson H. Metabolism of 14C-busulfan in isolated perfused rat liver. Eur. J. Drug Metab. Pharmacokinet. 12(1), 71-76 (1987). (Pubitemid 17120684)
9. Gibbs JP, Czerwinski M, Slattery JT. Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione S-transferases. Cancer Res. 56(16), 3678-3681 (1996). (Pubitemid 26272012)
10. Srivastava A, Poonkuzhali B, Shaji RV et al. Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood 104(5), 1574-1577 (2004). (Pubitemid 39166540)
11. Goekkurt E, Stoehlmacher J, Stueber C et al. Pharmacogenetic analysis of liver toxicity after busulfan/cyclophosphamide-based allogeneic hematopoietic stem cell transplantation. Anticancer Res. 27(6C), 4377-4380 (2007).
12. Gibbs JP, Murray G, Risler L, Chien JY, Dev R, Slattery JT. Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan. Cancer Res. 57(24), 5509-5516 (1997). (Pubitemid 28006757)
13. Gibbs JP, Yang JS, Slattery JT. Comparison of human liver and small intestinal glutathione S-transferase-catalyzed busulfan conjugation in vitro. Drug Metab. Dispos. 26(1), 52-55 (1998). (Pubitemid 28071324)
14. Malar R, Sjoo F, Rentsch K, Hassan M, Gungor T. Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients. Pediatr. Transplant. 15(6), 580-588 (2011).
15. McCune JS, Holmberg LA. Busulfan in hematopoietic stem cell transplant setting. Expert Opin Drug Metab. Toxicol. 5(8), 957-969 (2009).
16. Baker KS, Bostrom B, Defor T, Ramsay NK, Woods WG, Blazar BR. Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia. Bone Marrow Transplant. 26(6), 607-614 (2000).
17. Santos GW, Tutschka PJ, Brookmeyer R et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N. Engl. J. Med. 309(22), 1347-1353 (1983). (Pubitemid 14246556)
18. Bouligand J, Deroussent A, Simonnard N et al. Induction of glutathione synthesis explains pharmacodynamics of high-dose busulfan in mice and highlights putative mechanisms of drug interaction. Drug Metab. Dispos. 35(2), 306-314 (2007). (Pubitemid 46148745)
19. Younis IR, Elliott M, Peer CJ et al. Dehydroalanine analog of glutathione: an electrophilic busulfan metabolite that binds to human glutathione S-transferase A1-1. J. Pharmacol. Exp. Ther. 327(3), 770-776 (2008).
20. Vassord C, Lapoumeroulie C, Koumaravelou K, Srivastava A, Krishnamoorthy R. Endothelial cells do not express GSTA1: potential relevance to busulfan-mediated endothelial damage during haematopoietic stem cell transplantation. Eur. J. Haematol. 80(4), 299-302 (2008). (Pubitemid 351347585)
21. Zwaveling J, Press RR, Bredius RG et al. Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients. Ther. Drug Monit. 30(4), 504-510 (2008).
22. Elhasid R, Krivoy N, Rowe JM et al. Influence of glutathione S-transferase A1, P1, M1, T1 polymorphisms on oral busulfan pharmacokinetics in children with congenital hemoglobinopathies undergoing hematopoietic stem cell transplantation. Pediatr. Blood Cancer 55(6), 1172-1179 (2010).
23. Czerwinski M, Gibbs JP, Slattery JT. Busulfan conjugation by glutathione S-transferases a, m, and p. Drug Metab. Dispos. 24(9), 1015-1019 (1996).
24. Bertholle-Bonnet V, Bleyzac N, Galambrun C et al. Influence of underlying disease on busulfan disposition in pediatric bone marrow transplant recipients: a nonparametric population pharmacokinetic study. Ther. Drug Monit. 29(2), 177-184 (2007). (Pubitemid 46716183)
25. Lucena MI, Andrade RJ, Martinez C et al. Glutathione S-transferase M1 and T1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology 48(2), 588-596 (2008).
26. Datta SK, Kumar V, Ahmed RS, Tripathi AK, Kalra OP, Banerjee BD. Effect of GSTM1 and GSTT1 double deletions in the development of oxidative stress in diabetic nephropathy patients. Indian J. Biochem. Bio. 47(2), 100-103 (2010).
27. Kim SD, Lee JH, Hur EH et al. Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 17(8), 1222-1230 (2011).
28. Terakura S, Murata M, Nishida T et al. Increased risk for treatment-related mortality after bone marrow transplantation in GSTM1-positive recipients. Bone Marrow Transplant. 37(4), 381-386 (2006). (Pubitemid 43250472)
29. Mishra A, Chandra R, Mehrotra PK, Bajpai P, Agrawal D. Glutathione S-transferase M1 and T1 polymorphism and response to neoadjuvant chemotherapy (CAF) in breast cancer patients. Surg. Today 41(4), 471-476 (2011).
30. Oliveira AL, Rodrigues FF, Santos RE et al. GSTT1, GSTM1, and GSTP1 polymorphisms and chemotherapy response in locally advanced breast cancer. Genet. Mol. Res. 9(2), 1045-1053 (2010).
31. Askar I, Oktay MF, Gurlek A, Bac B. Protective effects of some antineoplastic agents on ischemia-reperfusion injury in epigastric island skin flaps. Microsurgery 26(3), 193-199 (2006).
32. Tsai-Turton M, Luong BT, Tan YM, Luderer U. Cyclophosphamide-induced apoptosis in COV434 human granulosa cells involves oxidative stress and glutathione depletion. Toxicol. Sci. 98(1), 216-230 (2007). (Pubitemid 47073834)
33. Rouissi K, Hamrita B, Kouidi S et al. In vivo prevention of bladder urotoxicity: purified hydroxytyrosol ameliorates urotoxic effects of cyclophosphamide and buthionine sulfoximine in mice. Int. J. Toxicol. 30(4), 419-427 (2011).
34. Almog S, Kurnik D, Shimoni A et al. Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination. Biol. Blood Marrow Transplant. 17(1), 117-123 (2011).
35. Hassan M, Ljungman P, Ringden O et al. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant. 25(9), 915-924 (2000). (Pubitemid 30255722)
36. Andersson BS, De Lima M, Thall PF et al. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol. Blood Marrow Transplant. 14(6), 672-684 (2008). (Pubitemid 351664062)
37. Andersson BS, Valdez BC, De Lima M et al. Clofarabine fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol. Blood Marrow Transplant. 17(6), 893-900 (2011).
38. Cantoni N, Gerull S, Heim D et al. Order of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCT. Bone Marrow Transplant. 46(3), 344-349 (2011).
39. Kerbauy FR, Tirapelli B, Akabane H, Oliveira JS. The effect of administration order of BU and CY on toxicity in hematopoietic SCT in humans. Bone Marrow Transplant. 43(11), 883-885 (2009).
40. Sadeghi B, Jansson M, Hassan Z et al. The effect of administration order of BU and CY on engraftment and toxicity in HSCT mouse model. Bone Marrow Transplant. 41(10), 895-904 (2008). (Pubitemid 351761692)
41. Hassan Z, Hellstrom-Lindberg E, Alsadi S, Edgren M, Hagglund H, Hassan M. The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo. Bone Marrow Transplant. 30(3), 141-147 (2002). (Pubitemid 34993852)
42. Sjoo F, Aschan J, Barkholt L, Hassan Z, Ringden O, Hassan M. N-acetyl-l-cysteine does not affect the pharmacokinetics or myelosuppressive effect of busulfan during conditioning prior to allogeneic stem cell transplantation. Bone Marrow Transplant. 32(4), 349-354 (2003). (Pubitemid 37038843)
43. Barkholt L, Remberger M, Hassan Z et al. A prospective randomized study using N-acetyl-l-cysteine for early liver toxicity after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 41(9), 785-790 (2008). (Pubitemid 351696342)
44. Gulbis AM, Culotta KS, Jones RB, Andersson BS. Busulfan and metronidazole: an often forgotten but significant drug interaction. Ann. Pharmacother. 45(7-8), e39 (2011).
45. Nilsson C, Aschan J, Hentschke P, Ringden O, Ljungman P, Hassan M. The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 31(6), 429-435 (2003). (Pubitemid 36511807)
46. Roedler R, Neuhauser MM, Penzak SR. Does metronidazole interact with CYP3A substrates by inhibiting their metabolism through this metabolic pathway? Or should other mechanisms be considered? Ann. Pharmacother. 41(4), 653-658 (2007). (Pubitemid 46625489)
47. Mazzei T. The difficulties of polytherapy: examples from antimicrobial chemotherapy. Intern. Emerg. Med. 6, 103-109 (2011).
48. Haas CE, Kaufman DC, Dicenzo RC. Effects of metronidazole on hepatic CYP3A4 activity. Pharmacotherapy 21(10), 1192-1195 (2001). (Pubitemid 32939093)
49. Wang JS, Backman JT, Kivisto KT, Neuvonen PJ. Effects of metronidazole on midazolam metabolism in vitro and in vivo. Eur. J. Clin. Pharmacol. 56(8), 555-559 (2000).
50. Cole SP, Deeley RG. Transport of glutathione and glutathione conjugates by MRP1. Trends Pharmacol. Sci. 27(8), 438-446 (2006). (Pubitemid 44051570)
51. Deeley RG, Cole SP. Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). FEBS Lett. 580(4), 1103-1111 (2006). (Pubitemid 43185290)
52. Costa J, Reis-Henriques MA, Castro LF, Ferreira M. Gene expression analysis of ABC efflux transporters, CYP1A and GSTa in Nile tilapia after exposure to benzo(a)pyrene. Comparative biochemistry and physiology. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 155(3), 469-482 (2012).
53. Shukla S, Chen ZS, Ambudkar SV. Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance. Drug Resist. Updat. 15(1-2), 70-80 (2012).
54. Wu SJ, Siu KC, Wu JY. Involvement of anion channels in mediating elicitor-induced ATP efflux in Salvia miltiorrhiza hairy roots. J. Plant Physiol. 168(2), 128-132 (2011).
55. Kim DH, Park JY, Sohn SK, Lee NY, Suh JS, Lee KB. The association between multidrug resistance-1 gene polymorphisms and outcomes of allogeneic HLA-identical stem cell transplantation. Haematologica 91(6), 848-851 (2006). (Pubitemid 44014559)
56. Pinto N, Ludeman SM, Dolan ME. Pharmacogenetic studies related to cyclophosphamide-based therapy. Pharmacogenomics 10(12), 1897-1903 (2009).
57. Henes JC, Mueller M, Pfannenberg C, Kanz L, Koetter I. Cyclophosphamide for large vessel vasculitis: assessment of response by PET/CT. Clin. Exp. Rheumatol. 29(1 Suppl. 64), S43-S48 (2011).
58. Boyce EG, Fusco BE. Belimumab: review of use in systemic lupus erythematosus. Clin. Ther. 34(5), 1006-1022 (2012).
59. De Vita S, Quartuccio L, Isola M et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 64(3), 843-853 (2012).
60. Su Y, Huang X, Wang S et al. Double negative Treg cells promote nonmyeloablative bone marrow chimerism by inducing T-cell clonal deletion and suppressing NK cell function. Eur. J. Immunol. 42(5), 1216-1225 (2012).
61. de Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH. Clinical pharmacokinetics of cyclophosphamide. Clin. Pharmacokinet. 44(11), 1135-1164 (2005). (Pubitemid 41483700)
62. de Jonge ME, Huitema AD, Van Dam SM, Rodenhuis S, Beijnen JH. Population pharmacokinetics of cyclophosphamide and its metabolites 4- hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with thiotepa and carboplatin. Ther. Drug Monit. 27(6), 756-765 (2005). (Pubitemid 44391731)
63. Giraud B, Hebert G, Deroussent A, Veal GJ, Vassal G, Paci A. Oxazaphosphorines: new therapeutic strategies for an old class of drugs. Expert Opin Drug Metab. Toxicol. 6(8), 919-938 (2010).
64. Rodriguez-Antona C, Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogene 25(11), 1679-1691 (2006).
65. Raccor BS, Claessens AJ, Dinh JC et al. Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo. Drug Metab. Dispos. 40(1), 54-63 (2012).
66. Hassan Z. Management of refractory hemorrhagic cystitis following hematopoietic stem cell transplantation in children. Pediatr. Transplant. 15(4), 348-361 (2011).
67. Upton A, Mccune JS, Kirby KA et al. Fluconazole coadministration concurrent with cyclophosphamide conditioning may reduce regimen-related toxicity postmyeloablative hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 13(7), 760-764 (2007). (Pubitemid 46902437)
68. Moreb JS, Muhoczy D, Ostmark B, Zucali JR. RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide. Cancer Chemother. Pharmacol. 59(1), 127-136 (2007). (Pubitemid 44796110)
69. Ekhart C, Doodeman VD, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet. Genomics 18(6), 515-523 (2008). (Pubitemid 351769919)
70. Bhatia K, Kaur M, Atif F et al. Aqueous extract of trigonella foenum-graecum L. ameliorates additive urotoxicity of buthionine sulfoximine and cyclophosphamide in mice. Food Chem. Toxicol. 44(10), 1744-1750 (2006). (Pubitemid 44216083)
71. Senthilkumar S, Yogeeta SK, Subashini R, Devaki T. Attenuation of cyclophosphamide induced toxicity by squalene in experimental rats. Chem. Biol. Interact. 160(3), 252-260 (2006).
72. Zhong S, Huang M, Yang X et al. Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus. Br. J. Clin. Pharmacol. 62(4), 457-472 (2006). (Pubitemid 44401529)
73. Kim I, Keam B, Lee KH et al. Glutathione S-transferase A1 polymorphisms and acute graft-vs.-host disease in HLA-matched sibling allogeneic hematopoietic stem cell transplantation. Clin. Transplant. 21(2), 207-213 (2007). (Pubitemid 46505728)
74. Mcdonald GB. Review article: management of hepatic disease following haematopoietic cell transplant. Aliment Pharmacol. Ther. 24(3), 441-452 (2006). (Pubitemid 44051320)
75. Hansen RJ, Ludeman SM, Paikoff SJ, Pegg AE, Dolan ME. Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals. DNA Repair 6(8), 1145-1154 (2007). (Pubitemid 47058392)
76. Nagasubramanian R, Hansen RJ, Delaney SM et al. Survival and tumorigenesis in O(6)-methylguanine DNA methyltransferase-deficient mice following cyclophosphamide exposure. Mutagenesis 23(5), 341-346 (2008).
77. Lee SM, Lee EJ, Ko YH, Lee SH, Maeng L, Kim KM. Prognostic significance of O-6-methylguanine DNA methyltransferase and p57 methylation in patients with diffuse large B-cell lymphomas. APMIS 117(2), 87-94 (2009).
78. Perini P, Calabrese M, Rinaldi L, Gallo P. The safety profile of cyclophosphamide in multiple sclerosis therapy. Expert Opin Drug Saf. 6(2), 183-190 (2007). (Pubitemid 46380812)
79. Rinaldi L, Perini P, Calabrese M, Gallo P. Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks. Neurol. Sci. 30, 171-173 (2009).
80. White ES, Lynch JP. Pharmacological therapy for Wegener's granulomatosis. Drugs 66(9), 1209-1228 (2006). (Pubitemid 44050436)
81. Ekhart C, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD. Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin. Pharmacogenet. Genomics 18(11), 1009-1015 (2008).
82. Lawson M, Vasilaras A, De Vries A, Mactaggart P, Nicol D. Urological implications of cyclophosphamide and ifosfamide. Scand. J. Urol. Nephrol. 42(4), 309-317 (2008).
83. Devi A, Devaraj H. Induction and expression of GST-Pi foci in the liver of cyclophosphamide-administered rats. Toxicology 217(2-3), 120-128 (2006). (Pubitemid 41773827)
84. Kim SH, Lee IC, Lim JH et al. Protective effects of pine bark extract on developmental toxicity of cyclophosphamide in rats. Food Chem. Toxicol. 50(2), 109-115 (2012).
85. Todorova V, Vanderpool D, Blossom S et al. Oral glutamine protects against cyclophosphamide-induced cardiotoxicity in experimental rats through increase of cardiac glutathione. Nutrition 25(7-8), 812-817 (2009).
86. Al-Hashmi S, Hassan Z, Sadeghi B, Rozell B, Hassan M. Dynamics of early histopathological changes in GVHD after busulphan/cyclophosphamide conditioning regimen. Int. J. Clin. Exp. Pathol. 4(6), 596-605 (2011).
87. Kalhorn TF, Howald WN, Cole S et al. Rapid quantitation of cyclophosphamide metabolites in plasma by liquid chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 835(1-2), 105-113 (2006).
88. McCune JS, Adams D, Homans AC, Guillot A, Iacono L, Stewart CF. Cyclophosphamide disposition in an anephric child. Pediatr. Blood Cancer 46(1), 99-104 (2006). (Pubitemid 41779325)
89. Muzio G, Trombetta A, Maggiora M et al. Arachidonic acid suppresses growth of human lung tumor A549 cells through down-regulation of ALDH3A1 expression. Free Radical Bio. Med. 40(11), 1929-1938 (2006). (Pubitemid 44250821)
90. Bacolod MD, Lin SM, Johnson SP et al. The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide. Curr. Cancer Drug Targets 8(3), 172-179 (2008). (Pubitemid 351666854)
91. Hingorani P, Zhang WD, Piperdi S et al. Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma. Cancer Chemother. Pharmacol. 64(4), 733-740 (2009).
92. Makia NL, Bojang P, Falkner KC, Conklin DJ, Prough RA. Murine hepatic aldehyde dehydrogenase 1a1 is a major contributor to oxidation of aldehydes formed by lipid peroxidation. Chem. Biol. Interact. 191(1-3), 278-287 (2011).
93. Sladek NE. Aldehyde dehydrogenase-mediated cellular relative insensitivity to the oxazaphosphorines. Curr. Pharmaceut. Design 5(8), 607-625 (1999). (Pubitemid 29484992)
94. Martinez C, Martin F, Fernandez JM et al. Glutathione S-transferases mu 1, theta 1, pi 1, alpha 1 and mu 3 genetic polymorphisms and the risk of colorectal and gastric cancers in humans. Pharmacogenomics 7(5), 711-718 (2006). (Pubitemid 44219401)
95. Katoh T, Yamana Y, Tsuji M, Watanabe M. Genetic polymorphisms of human cytosol glutathione S-transferases and prostate cancer. Pharmacogenomics 9(1), 93-104 (2008). (Pubitemid 351560533)
96. Altinisik J, Balta ZB, Aydin G, Ulutin T, Buyru N. Investigation of glutathione S-transferase M1 and T1 deletions in lung cancer. Mol. Biol. Rep. 37(1), 263-267 (2010).
97. Sharda SV, Gulati S, Tripathi G et al. Do glutathione-S-transferase polymorphisms influence response to intravenous cyclophosphamide therapy in idiopathic nephrotic syndrome? Pediatr. Nephrol. 23(11), 2001-2006 (2008).
98. Funke S, Timofeeva M, Risch A et al. Genetic polymorphisms in GST genes and survival of colorectal cancer patients treated with chemotherapy. Pharmacogenomics 11(1), 33-41 (2010).
99. Tsuda H, Futakuchi M, Fukamachi K et al. A medium-term, rapid rat bioassay model for the detection of carcinogenic potential of chemicals. Toxicol. Pathol. 38(1), 182-187 (2010).
100. Tran A, Bournerias F, Le Beller C et al. Serious haematological toxicity of cyclophosphamide in relation to CYP2B6, GSTA1 and GSTP1 polymorphisms. Br. J. Clin. Pharmacol. 65(2), 279-280 (2008). (Pubitemid 351171274)
101. Afsar NA, Ufer M, Haenisch S et al. Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients. Eur. J. Clin. Pharmacol. 68(4), 389-395 (2012).
102. Rossi D, Rasi S, Franceschetti S et al. Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. Leukemia Research Fund, U.K. Leukemia 23(6), 1118-1126 (2009).
103. Sweeney C, Ambrosone CB, Joseph L et al. Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment. Int. J. Cancer 103(6), 810-814 (2003). (Pubitemid 36110239)
104. Barahmani N, Carpentieri S, Li XN et al. Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma. Neuro Oncol. 11(3), 292-300 (2009).
105. Nakajima M, Komagata S, Fujiki Y et al. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenet. Genomics 17(6), 431-445 (2007). (Pubitemid 46763388)
106. Xie HJ, Yasar U, Lundgren S et al. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J. 3(1), 53-61 (2003). (Pubitemid 36432466)
107. Takada K, Arefayene M, Desta Z et al. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum. 50(7), 2202-2210 (2004). (Pubitemid 38924398)
108. Rocha V, Porcher R, Fernandes JF et al. Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia. Leukemia Research Fund, U.K. Leukemia 23(3), 545-556 (2009).
109. Huang Z, Roy P, Waxman DJ. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem. Pharmacol. 59(8), 961-972 (2000). (Pubitemid 30110812)
110. Dickinson AM. SNPs and GVHD prediction: where to next? Blood 119(22), 5066-5068 (2012).
111. Mccune JS, Batchelder A, Deeg HJ et al. Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality. Biol. Blood Marrow Transplant. 13(7), 853-862 (2007). (Pubitemid 46902444)
112. Chien JW, Zhang XC, Fan W et al. Evaluation of published single nucleotide polymorphisms associated with acute GVHD. Blood 119(22), 5311-5319 (2012).